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INTRODUCTION
An immense amount of research into the nature and
epidemiology of poliomyelitis has been carried out during
the last 30 or so years. This followed the discovery that
poliomyelitis is due to infection with a specific virus and
that a condition similar to that of paralytic poliomyelitis
in man may be induced in monkeys by inoculation of their
central nervous system with infective material. As a result
of this research it soon became evident to many that the
only hope of effectively controlling the disease lay in the
development of an efficient vaccine.
Attempts were made by Brodie in 1934 and Kolmer in
1935 to prepare a poliovaccine, similar to that of rabies
vaccine. They used suspensions of infected monkey nervous
tissue in which the virus particles had been inactivated
by chemical agents. It was not until 1949, however, when
Enders et al. I published their studies on the artificial growth
of poliovirus in high titre on monkey kidney-tissue culture,
that the production of poliovaccine became a reasonably
feasible proposition. This discovery was of fundamental
importance in the development of poliovaccine. Also of
basic importance was the work of Bodian et al.~ who
showed that there were 3 distinct immunological types of
poliovirus. The Typing Committee of the National Foun-
dation of Infantile Paralysis of the USA then proved that,
although there were numerous strains of poliovirus which
differed greatly in their virulent properties, each strain
belonged to one or other of the 3 types. This work made
it clear that any effective vaccine would have to be
trivalent. It then had to be decided what type of vaccine
should be produced - a living attenuated or a dead inacti-
vated vaccine.
On general principles, many authorities believed that
the best hope of developing a really effective prophylactic
agent against poliomyelitis lay in the production of a live
vaccine. Live poliovaccine is, however, attended by two
possible dangers, viz. (I) the vaccine virus may not be
sufficiently attenuated and so may cause paralytic disease
in unduly susceptible persons; and (2) the vaccine virus,
being excreted from the alimentary tract of those vacci-
nated, might be passed on to others and, gaining in
virulence by such passage, might ultimately produce
paralytic disease in them.
At that stage it was obvious that several years of very
careful and intensive research would have to be carried
out before a live attenuated poliovaccine, the safety of
which to the individual and the community could be
guaranteed beyond all doubt, could be produced. It thus
seemed that the development of a 'dead' vaccine would
be the quickest answer to this urgent problem. There
* This paper is published with the permission of the
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could be little doubt of the safety of such a vaccine, though
there might be doubt as to its probable efficacy.
SALK VACCt E
Salk then developed his formalin-inactivated vaccine. Thi
was soon conclusively proved, by the now famous large-scale
field trIals earned out in the USA during 1954, not only to
be safe but to be 60 - 70o~ effective in preventing paralytic
polIomyelItl . FollowLllg the report by Francis3.' of these trials
a mass vaccination campaign was immediately tarted i~
America. However, this campaign soon experienced a very
serIOUS setback due to a numoer of paralytic cases unex-
pectedly occurring among vaccinated people. These were later
proved to be due to contamination of some of the batches
of vaccine with live virulent virus. An immediate official
investigation was carried out and it was shown that the method
of ina<:tivation of the vaccine virus was not foolproof, as wa
first thought, and that the safety tests which had been used
were inadequate.
After more stringent control of the processing of the vaccine
had been introduced and more elaborate safety tests enforced
a mass vaccination campaign again slowly proceeded:
SInce then many millions of children have been successfully
Inoculated with Salk vaccine throughout the world and the
vaCCIne has proved to be the safest and most innocuous
vaccine in routine use today. Moreover, its potency has been
so Improved that a 90% immunity ~ paralysis may be expected
after 3 or more properly-spaced injections. There can thus
be no doubt whatever about the great success of the Salk
vaccine. Inactivated vaccine, however, ha its limitation and
there are a number of authorities who still believe that the
final. conquest of poliomyelitis will be achieved by a live
vaccme.
LIVE VACCINE
One of the most important discoveries of the immortal
Louis Pasteur was the rationale for the production of live
vaccines. These vaccines are composed of living micro-
organisms, the virulence of which for a particular species
of animal has been attenuated by such means as passage
through resistant animals of another species. This attenu-
ation causes them to lose their ability to produce serious
disease in the original animal species but allows them to
retain their ability to provoke a protective immunity.
Infection with such attenuated micro-organisms induces
subclinical disease, so that the organisms multiply in the
tissues and, by sustained antigenic stimulation, produce
an effective immunity in a natural way. Thus it is that
the most efficient viral vaccines are smallpox and yellow-
fever vaccines, both of which are composed of living
attenuated organisms. As natural immunity to paralytic
poliomyelitis, which lasts throughout life, is normally
acquired by subclinical infection with wild strains, there
is every theoretical hope that live poliovaccine will produce
a relatively solid and lasting immunity.
Early Research
Because of the great promise offered by a living polio-
vaccine, certain research workers of vision have devoted
961
962 S.A. MEDICAL JOURNAL 12 November 1960
all their efforts towards the development of such a vaccine
and have refused to be deviated from their task by the
apparently great success of the 'dead' vaccine. Foremost
among these workers has been Koprowski. In the late
1940ss he attenuated selected strains of poliovirus by serial
passage through rodents. By inoculation of the central
nervous system of monkeys with these virus strains he
proved that they had become attenuated, in that their
ability to produce progressive lesions in the monkeys was
greatly diminished. Such biological tests on monkeys,
though they have certain obvious defects, are still the
best laboratory means of distinguishing between virulent
and avirulent strains. Eventually, feeling confident that
his attenuated strains had lost their ability to cause paralytic
disease in Man, he fed a suspension of infected cotton-
rat brain to a 6-year-old boy. This was in February 1950,
and it is the first recorded case of the use of live polio-
vaccine in Man. The boy developed an intestinal infection
with the virus but showed no signs of disease and gradually
produced specific neutralizing antibodies in his blood.
The experiment, therefore, appeared to be successful and
soon 20 subjects were fed vaccine without any ill effects.
Since these initial and most important experiments by
Koprowski, an immense amount of research on live polio-
vaccine has been carried out by him and by other workers.
Other methods of attenuating poliovirus have been
developed, such as the adaptation of certain strains to the
developing chick embryo. Tissue culture has been of the
greatest help in studying and propagating various strains,
and the plaque technique of Dulbecco,6 whereby the
progeny of individual virus particles may be isolated,
has proved invaluable in the selection and purification of
strains.
Many of the strains selected have had to be discarded
because, on monkey test, they have proved to be in-
sufficiently avirulent. Others, again, have had to be dis-
carded because, though they have been proved to be
avirulent, they have also lost some of their important
specific antigenic properties.
Later Research
As a result of much meticulous and time-consuming
laboratory work and intensely studied small-scale experi-
ments on humans in closed communities, confidence was
soon obtained in the safety of several live poliovaccines.
This enabled the Expert Committee on Poliomyelitis of
the World Health Organization to advise in 1957
that a stage of development in these vaccines had now
been reached where large-scale studies on humans were
justified in those countries where suitable epidemiological
conditions prevailed.
MAIN LIVE-VACCINE STRA.INS
Three different sets of carefully selected attenuated strains
were then used for large-scale experiments, viz. (1) the
Koprowski strains, (2) the Cox strains, and (3) the Sabin
strains. Each of these strains has been named after its
originator.
These 3 sets of strains, though all regarded as safe
and antigenically potent, have shown considerable differ-
ences in their neurovirulent properties as tested in
monkeys. The Sabin strains have, however, been shown
consistently by such tests to be the most avirulent.
I. Koprowski Strains
The first large-scale experiments with live poliovaccine were
conducted with the Chat (Type I) strain of Koprowski in the
Belgian Congo, commencing in 1957.7 By early 1959 some
46,000 African children under the age of 5 years had been
vaccinated in Leopoldville. The vaccine used appeared to be
perfectly safe in that it caused no cases of paralytic polio-
myelitis or other complications among the vaccinated subjects
or their contacts. The immunity response, as shown by the
development of specific antibodies in the serum of the
vaccinated children, was, however, somewhat disappointing.
Only about 60% gave positive reactions as compared with
90 - 95% obtained in studies with the Chat strain elsewhere.
This partial failure was attributed to interference with the
vaccine by other enterovirus infections which are: common in
children living in a tropical and unhygienic environment. When
a poliomyelitis epidemic occurred in Leopoldville shortly after
the vaccination campaign had commenced, the vaccine appeared
to have proved of definite protective value. Of 99 paralytic
cases with 4 deaths in this epidemic, 89 cases occurred in
non-vaccinated children. However, it has been considered that
the numbers involved were too small to allow of a proper
statistical evaluation. This experience in the Congo. strongly
suggests that the live-virus vaccine used was of definite pro-
tective value. Also, there was no evidence to indicate that the
vaccine was unsafe either for the individual or the community.
Live-virus vaccine composed of Koprowski strains has also
been employed in Poland:s This vaccine was used only on
a small number of subjects in 1958 but since 1959 it has been
employed on a mass scale, so that nearly a million children
were vaccinated by the end of the year. Only Types I and ill
strains were used and no Type H. The results appeared to be
most promising, but a detailed report of the efficacy and
safety of live poliovirus as used in Poland is still awaited.
More recently a report has been published by Pagnano
et al.9 on the routine use of live-virus vaccine composed of
all 3 types of the Koprowski strains. This was given to 850
normal children, aged from It months to 6 years. They were
mainly Negroes, from a low-income group, living in Phila-
delphia, USA. One, 2 or 3 types of vaccine were fed at monthly
intervals. Of the children under 6 months of age, 91 - 100';0
had a significant antibody response and, in children over 6
months, who had no antibodies before vaccination, there was
a significant rise in titre in 84 - 100%. Serologically, therefore,
the vaccine was efficacious; it also appeared to be safe in
that no case of poliomyelitis occurred in a vaccinated child
or in his household.
Thus the evidence available concerning the Koprowski strains
is that they are safe and effective for use in live-virus vaecine
but the results of the mass trials in Poland must be awaited
before a final opinion is given. Perhaps these strains will
prove as safe as, and possibly more effective than, the Sabin
strains.
2. Cox Strains
The Cox strains of poliovirus have been used in live vaccine
on a large scale in recent years in Latin America (Colombia,
Nicaragua and Costa Rica).lo In these countries different pro-
grammes have been followed. In some cases monovalent feed-
ings of all 3 types have been given separately at intervals of
3 - 4 weeks, while in other cases trivalent vaccine has been
fed either once only, or twice at an interval of 8 weeks
between doses. In Colombia, among 7,000 children who were
fed with 3 successive doses of the 3 types of vaccine, 91 %
responded serologically to Type I, 72% to Type 11 and 87%
to Type IlL while those with antibodies showed a booster
effect from the vaccine. Serologically, therefore, the vaccine
appeared to be efficacious.
In Nicaragua vaccine was fed to children during a Type n
epidemic and it appeared to be of value in preventing
paralytic cases. In Costa Rica, where the vaccine was used
during an epidemic, the attack rates among the vaccinated
and non-vaccinated were 7 and 100 per 100,000 of population
respectively.
Thus in the Latin American countries the Cox type of
vaccine appears to have been effective, though there is little
information about its safety.
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Cox vaccine was recently used in large-scale field trials
in Florida, USA, and it was learnt at the Copenhagen con-
gress, that, though the incidence of paralytic poliomyelitis
had decreased in Florida during the last 5 years, several
unexpected cases had occurred in young adults in association
with this trial. The development of paralytic complications
does not depend solely on the virulence of the invading virus
but also on the susceptibility of the host. It appears that the
person who reaches early adult age without having acquired
an immunity is the one most likely to suffer nervous-system
lesions after a poliomyelitis infection. The question, therefore,
arises whether the cases were due to the vaccine virus and, if
0, whether this virus had gained an enhanced virulence by
passage through the vaccinated children.
It was also reported at the congress that Cox trivalent
vaccine had recently been used in West Berlin in the face
of an epidemic. Over 250,000 children, representing about
half the preschool children of the city, had been fed the
vaccine. Following this, 34 cases of poliomyelitis were notified
of which 23 were in the vaccinated children. Were any of
these cases due to the vaccine?
It may well be that none of the cases occurring in Florida
or West Berlin were due to the attenuated-vaccine virus but
that all were due to virulent wild strains, i.e. the infections
were purely coincidental with the vaccine campaigns. When-
ever vaccinations are carried out there is always the possibility
of coincidental infections occurring. This is inevitably so if
there is a contemporaneous epidemic. These incidents in
Florida and West Berlin cannot, however, be ignored. The pro-
blem of safety can only be solved by extensive epidemiological
investigations which include elaborate laboratory studies. An
answer to these important questions must, therefore, be post-
poned until such investigations have been completed and
reported in detail.
3. Sabin Strains
The Sabin strains were developed by Dr. A. B. Sabin of the
University of Cincinnati, USA and, as previously mentioned.
have proved to be the most avirulent on monkey testing of
the 3 sets of live-virus strains used in present-day live
poliovaccine production. Laboratory evidence, therefore, sug-
gests that they should be the safest strains for the preparation
of vaccines.
After intensively studied small-scale experiments on humans
in the USA and the USSR, the USSR Ministry of Health,
being impressed by the harmlessness and efficacy of these
Sabin strains as shown by these experiments, authorized their
use in large-scale experiments with live virus vaccine in the
republics of the USSR during 1959.8 Starting with the Republic
of Estonia where there had been a recent epidemic, some 15
million persons under the age of 20 years were soon fed with
the vaccine. So successful did this experiment prove that it
was decided in future to abandon Salk vaccine and to switch
over completely to live vaccine. Thus, during the first half of
1960. another 60 million persons were fed this vaccine in
Russia. as well as several million persons in Eastern European
countries.
Live virus composed of Sabin strains has also been used in
Mexico and in Singapore. .
At the Fifth International Poliomyelitis Congress held in
Copenhagen (26 - 28 July 1960) detailed reports of all these
experien~es with Sabin-type vaccine were given.
Russian Trials
In the Russian trials there was no control group as in the
American field trials of 1954 with Salk vaccine. The Russian
campaign was a mass one and the vaccinations were purely
voluntary. The response of the population was remarkably
good. Serological surveys, to determine the prevaccination
immunity of the population, were carried out and an effective
surveillance programme was pot into operation. In Tashkent
the vaccine was given in the face of an epidemic. The vaccine
was administered in a liquid form or in candy and it was
shown that the candy kept well at 4°C. for more than a
month. Six different schedules of feeding were used by the
Russians.l1 The Sabin-recommended schedule of first feeding
Type I, then Type III and finally Type 11 at monthly intervals
appeared to be superior to feeding trivalent vaccine. A
schedu1e of Type I followed by Types 11 and III and then by
Types I, II and Ill, so that each person received 2 feedings
of each type, appeared to give the best results. However, if
vaccine was given at monthly intervals, the difference between
the different schedules appeared to be negligible. If a polio-
myelitis epidemic is imminent 2 feedings of trivalent vaccine
are probably best. With shortened intervals between feedings
the viruses tended to interfere with each other and, in par-
ticular, Type 11 interfered with the 'takes' of the other types.
Because of occasional interference by other enteroviruses, it
is also thought advisable to carry out feedings during the
winter months.
10 their experience the Russians12 claimed that the vaccine
proved to be completely harmless and to have shown no
reversion to a virulent state. They noted no local or systemic
reactions to the vaccine and they claimed that the epidemi-
ological effectiveness of the live Sabin vaccine substantially
exceeded that of Salk vaccine. Unfortunately, since there
was no control group, the incidence of paralytic poliomyelitis
in vaccinated and unvaccinated persons could not be compared.
The overall incidence of the disease, however, in comparison
with the incidence over the last 5 years, showed a dramatic
fall. The serological responses compared favourably with those
obtained by Salk vaccine. One month after feeding, t - t of
those vaccinated developed antibodies, and this proportion
became even higher after 3 months.
The Russian delegates to the Copenhagen congress also
stressed the cheapness of the vaccine and the great ease with
which a mass campaign employing live-virus vaccine could
be rapidly carried out.
By means of compulsory vaccination of all the population
at risk under strict government supervision, the Ministry of
Health hopes to eliminate the reservoir of wild pathogenic
strains in Russia and so liquidate the disease.
Sabin was in close liaison with the Russian Ministry of
Health during the trials and appeared to be much impressed
by the efficiency with which the campaign was carried out.
Dr. D. Horstmann,S Associate Professor of Preventive
Medicine and Pediatrics of Yale University School of Medicine,
USA, visited Russia, Poland and Czechoslovakia in 1959 in
agreement with the ministries of health of these countries
and on behalf of the WHO, to evaluate the results of these
vaccination programmes. She states in her report that surveil-
lance in Russia was very efficient and she considered that,
under the system adopted, it was most unlikely that any
paralytic cases were missed. She concluded that the attenuated
live vaccines used in these large-scale experiments appeared
to have been safe both for the individual and the community.
She also felt that the fall in the incidence of paralytic polio-
myelitis indicated that the vaccine was effective though,
because of the absence of controls, it was difficult to gauge
its effectiveness accurately.
Singapore Trials
At the congress, Hale13 reported on his Singapore experience.
In 1958 there was a Type I epidemic in this city. He fed 50%
of the population at risk, some 200,000 children between the
ages of 3 months and 10 years, with live vaccine composed
of Sabin Type II strain only. The object of this was to be
able to distinguish clearly between paralytic cases due to the
epidemic Type I strain and any Type II cases which might
have been caused by the vaccine. No cases of Type I paralysis
occurred in the vaccinated children between the 8th and the
34th day after feeding. This experiment showed how a harmless
intestinal infection by Type 11 avirulent virus prevented Type T
infection from occurring. This was due to the phenomenon
of interference, i.e. the Type Tl virus blocked the receptors
and so prevented a Type I infection establishing itself. He
concluded that, because of mutual interference between entero-
viruses, it is obviously desirable to conduct vaccination cam-
paigns with live poliovirus at times of the year when infection
with enteroviruses is minimal.
Mexican Trials
An account was also given at the congress of laboratory
and field experience with Sabin strains In 4 Mexican cities.!~
It was noted that interference with other enteroviruses
occurred again leading· to a certain failure rate. Nevertheless,
serological tests on paired sera indicated that the strains
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used were highly immunogenic and that the conversion rate
for Type 1 was 84%, Type If, 81 % and Type lll, 73%. In
Mexico City only 17% of the children at risk were immunized
and in Guadalajara, 30%.
These proportions were too small to influence the dissemina-
tion of wild paralytogenic strains. To banish paralytic polio-
myelitis in a community it was calculated that at least 80%
of the susceptible population should be vaccinated in the
shortest possible time.
In Monterrey and Puebla it was noted that there was a
striking difference between the number of expected cases and
the number of observed cases in the vaccinated children. This
indicated that the vaccine was effective, though conditions did
not allow the effective rate to be statistically calculated.
Finally Dr. Sabinl5 gave an inspiring account of the effect
of rapid mass immunization of the population of Toluca,
Mexico, with live oral vaccine under conditions in which
massive enteric infection with other viruses was prevalent.
Because of prevailing hygienic conditions in Toluca, all children
acquired an immunity at a relatively early age by natural
infection with circulating wild viruses. But this was at a cost
of many paralytic case a year. Sabin, in 2 feedings separated
by an interval of 6 - 8 weeks, fed all children under 5 years
in Toluca with trivalent vaccine. Paralytic cases were brought
to a dramatic end. He had artificially produced a herd
immunity in a few months which would normally take as many
years to acquire by natural means. Later he showed that
almost all polioviruses, tame and wild strains, had disappeared
from Toluca. The reservoir for poliomyelitis was thus elimi-
nated, and poliomyelitis had been banished from the city by
this mass campaign. What has been done in Toluca can be done
elsewhere. Sabin stressed that in future in Toluca it would
be necessary to immunize all infants below the age of 6 months
because they would now have little or no opportunity of
acquiring infection by natural means.
Thus it may be concluded that more than 60 million Russians
have proved the safety and efficacy of attenuated live polio-
vaccine composed of Sabin strains, and the city of Toluca
has clearly indicated how poliomyelitis may be totally
vanquished.
INACTIVATED versus LIVE ATTENUATED POLIOVACCI 'E
Inactivated Salk poliovaccine has proved to be a great
success. It is a safe and innocuous vaccine and its use
has substantially reduced the incidence of paralytic polio-
myelitis. The immunity produced after a full and properly
spaced course of treatment with this vaccine is, however,
relative, in that it reduces the incidence of paralysis at best
by only 80 - 90%.
Live poliovaccine causes a temporary but harmless
infection similar to that of the natural disease and, there-
fore, it is to be hoped that the resultant immunity will
be more solid and lasting than that of the Salk vaccine.
Inactivated poliovaccine prevents paralytic complications
after infection by stimulating the production of circulating
antibodies which intercept the virus particles in their
passage in the blood stream from the intestinal tract to
the central nervous system. This vaccine does not, how-
ever, prevent intestinal infection occurring. Therefore, it
does not interfere with the natural circulation of polio-
viruses in the community or reduce the reservoir of
infection.
The live vaccine causes a temporary intestinal infection
which lasts for several weeks and which not only stimulates
the production of circulating antibodies but, as shown by
many workers, also induces a local intestinal resistance
S0 that the subject cannot be reinfected. As the polio-
viruses normally exist only in the gastro-intestinal tract
of Man, mass vaccination of all susceptible members of
a community with live vaccine must eliminate the reservoir
of infection. That poliovirus may thus be banished has
been proved by the experience of Toluca, Mexico. Live
poliovaccine not only protects the individual from polio-
myelitis infection but, when mass vaccination is carried
out, it also protects him and the community by preventing
infections from being acquired. This is obviously a matter
of great public-health importance. To achieve total banish-
ment of polioviruses from a community, it has been
estimated that at least 80% of the population at risk
should be successfully immunized with live vaccine, as
previously mentioned. This is a practical proposition that
may readily be achieved.
Because passively transferred antibodies from the
mother neutralize the circulating antigens, it has not been
found practical to immunize infants effectively below the
age of 6 months with inactivated vaccine. Such infants,
however, may be successfully immunized with live vaccine.
A good immunity to paralytic poliomyelitis takes several
months to achieve with present-day inactivated vaccine,
but protection from poliomyelitis infection may be obtained
in little more than a week by use of a live vaccine. Thus
an epidemic may be rapidly aborted by the prompt use
of such a vaccine.
An annoying disadvantage of any parenterally adminis-
tered agent is the occurrence of allergic complications.
Inactivated vaccine is given by injection and, although
the Salk vaccine is almost a pure aqueous suspension of
formalinized virus particles, it may contain traces of anti-
biotics or monkey-kidney protein from the culture media
in which the virus was grown. On occasion, these sub-
stances may induce allergic reactions in sensitized persons.
As live poliovirus is fed by mouth, these complications
should be eliminated by its use.
In all public-health measures to be applied on a large
scale, economic questions are of great importance. Here
live poliovaccine has the advantage over the inactivated
form in that it is much cheaper to produce. Because the
potency of the inactivated vaccine used up to this time
has not been as high as desired and because several
injections must be given to obtain a good immune response,
attempts have been made to produce a more concentrated
form of the vaccine. These attempts have been successful
and concentrated vaccine which gives a satisfactory anti-
body response after only 2 injections has been experimen-
tally produced.16 Salk hirnself,li at the recent Copenhagen
congress, optimistically prophesied that it may be possible
to produce so highly potent a concentrated vaccine in
the near future that only 1 injection would be necessary
to produce an adequate immunity. A concentrated vaccine
must be purified to eliminate possible serious contami-
nation with monkey-kidney protein or other undesirable
antigenic materials, which may accumulate in the con-
centrated vaccine in significant amounts. It is thus to be
expected that concentration and purification of these new
inactivated vaccines will add considerably to the. cost of
their production.
Inactivated vaccine must at present be administered by
a series of injections, whereas the live virus is simply fed
to children in the form of a syrup or candy - a. far
cheaper procedure and one which should allow of far
easier coverage of the population. True, the live vaccine
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must be kept continuously at low temperature until
immediately before its administration; otherwise it may
rapidly lose potency. This means that it must be trans-
ported packed with dry ice in suitably insulated containers
and then stored at low temperature until used. It is best
stored in a 'deep-freeze' but may be stored in the freezing
compartment of a domestic refrigerator for up to a month
without undue loss of potency. These difficulties in the
transportation and storage of live poliovaccine may make
it impractical for private medical practitioners to deal with
individual cases. Periodic mass vaccination campaigns,
carried out by public-health authorities, can readily over-
come all these difficulties.
There is no danger today of inactivated vaccine, which
has been properly processed and subjected to routine
safety tests, being contaminated with live micro-organisms.
Micro-organisms which may contaminate live vaccine can
also be readily excluded and their absence proved by
suitable testing. Special difficulties, however, arise in
respect of 2 contaminants, viz. (I) poliovirus particles of
enhanced virulence, and (2) 'simian agents'.
It is most important that the final vaccine should con-
tain no virus particles that differ from the original
attenuated strains. Before any batch of vaccine is issued
it is, therefore, necessary to carry out elaborate biological
tests on an adequate number of monkeys to ensure that it is
composed only of attenuated poliovirus particles. Recently,
tests based on genetic markers have also been elaborated
to differentiate between virulent and avirulent strains, but
the exact value of these tests is still to be accurately
determined.
'Simian agents' are viruses of monkey origin which are
frequently found as contaminants in monkey-kidney tissue
cultures and, therefore, are extremely difficult to keep out
of poliovaccines. Their presence in cell cultures used for
the preparation of inactivated virus is of no real con-
sequence, since they are 'killed' in the processing, but there
has been doubt as to their significance in cultures used
to prepare live vaccine. These agents have been fairly
extensively studied in recent years and, though not fully
classified, most of them appear to be quite harmless and
incapable of causing disease in Man or experimental
animals. Theoretically they should be excluded from live
poliovaccine but whether it is necessary or practical to
do so is a matter of some doubt. Certainly some of
the live vaccines employed in Russia and elsewhere were
contaminated with one or other of these agents and no ill-
effects were observed in the many millions vaccinated. The
question of excluding them from vaccine may thus appear
to be more of academic than practical interest. Further-
more, any remote danger is minimized by the fact that
the vaccine is given by mouth and not by injection. As
was pointed out in Copenhagen, if the great Jenner had
been hampered in his work by all sorts of remote
theoretical considerations, many years would have elapsed
before smallpox vaccine was put into practical use and
countless more people would have died unnecessarily of
this foul disease as the result of such delay. Thus, though
every endeavour should be made to exclude contamination
of live poliovaccine with these agents, their possible
presence in the vaccine may not prove to be of any real
consequence.
Inactivated vaccine affects only the individual to whom
it is administered, but live poliovaccine is excreted for
several weeks in the stools of those vaccinated and so
may be passed on to others. From an epidemiological
study of live virus in a small community, PauPs was struck
by the great ease and speed of intrafamily spread of the
vaccine virus; he also found evidence to how that extra-
family spread occurred. The use of live poliovaccine
represents a radical departure from previous orthodox
practice in preventive medicine in that the vaccine becomes
spread beyond the original vaccinated population. In this
way others become involuntarily infected and immunized.
Some authorities consider that this is an added advan-
tage in that it keeps the vaccine virus circulating in family
and small social groups until all susceptible members
become infected and immunized. Others see something
immoral in this involuntary vaccination of persons. To let
a tame strain of virus loose in a community in competition
with wild and virulent strains and so diminish the hazards
of normal natural immunization, which may lead to death
or the permanent crippling of children, cannot be reason-
ably looked upon as an immoral procedure in this modern
age. The main fear that the vaccine virus may gain
significantly in virulence in its passage from person to
person, and so become a danger to the community, seems
to have been completely negated by the experience gained
in more than 60 million Russian subjects and several
million other children in whom the Sabin strains were
used.
It will thus appear clear that live poliovaccine compo ed
of Sabin strains, and probably Koprowski strains, is safe
and effective and offers many advantages, from a public
health point of view, over inactivated poliovaccine.
THE POStTIO 'I SOtrrH AFRICA
Inactivated Po/iovaccine
Following the serious postwar epidemic of poliomyelitis
in South Africa, a large sum of money was raised by
generous public subscription to establish a National
Foundation to fight poliomyelitis. This money was invested
in the South African Poliomyelitis Research Foundation
laboratories at Rietfontein, under the directorship of Dr.
James Gear, with the main objective of developing a
vaccine against poliomyelitis. The result is that South
Africa is one of the leading countries in the world in this
field. Thus, when the famous field trials of 1954 were
being conducted in the USA, the South African Polio-
myelitis Research Foundation laboratories had already
prepared a large amount of inactivated poliovaccine. This
vaccine was made available shortly after its relea e in
America so that South Africa was one of the first countries
to have ample stocks of vaccine and was able to launch
a vaccination campaign well before many of tbe mo t
important countries of Europe. South African inactivated
poliovaccine proved to be a great success - it was safe and
no accidents were recorded. Its potency as judged by
laboratory tests and serological assays in susceptible
children, compared most favourably with that of any
vaccine produced elsewhere. This vaccine bas been respon-
sible for a great reduction in th~ incidence of paralytic
poliomyelitis in South Africa.
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The South African Poliomyelitis Research Foundation
laboratories have also been to the fore in the production
of live attenuated poliovaccine, composed of Sabin strains.
Several million doses have been produced and subjected
to all the recommended laboratory safety tests with success.
With the permission of the Colonial Office of Great Britain,
200,000 doses of this vaccine have recently been used in
Mauritius to combat a poliomyelitis epidemic there.
Unfortunately the vaccine was administered only towards
the end of the epidemic so that its efficacy cannot be fairly
judged. It was, however, proved safe, since no significant
ill-effects occurred. More than a million doses of this
vaccine have also been used recently in Kenya; again
without any reported ill-effects, but also too recently to
judge its efficacy. As, however, it is composed of Sabin
strains, there is every reason to believe that it will prove
as efficacious as this type of vaccine has proved else-
where. Two million doses of this vaccine have now been
released by the Minister of Health for use in South Africa.
This is being done on the recommendation of the Public
Health Virological Advisory Committee which is perfectly
satisfied as to the safety of the vaccine. This recommen-
dation of the South African Committee is given added
confidence by the fact that, within a few days of its
making its recommendation, the Federal Public Health
Department of the USA authorized the release of live
poliovaccine, of Sabin strains only, in the USA.
The first batch being released in South Africa is
monovalent Type I vaccine because the most likely type
to cause any cases of poliomyelitis this summer is this one.
By using this vaccine now it is hoped to prevent paralytic
cases in the vaccinated communities. Batches composed
of the other types will be released later for use next
winter. It is recommended that all Europeans up to the
age of 30 years and all non-Europeans up to school-
leaving age be fed with this vaccine whether or not they
have received previous inoculations with inactivated
vaccine. The racial differentiation is made because sero-
logical evidence indicates clearly that non-European
children acquire a natural immunity at a much earlier age
than do the European.
The public money invested in the South African Polio-
myelitis Research Foundation is thus about to pay another
handsome dividend to the country. Once again this Foun-
dation has proved that it is an institution of which South
Africa can be justly proud.
CONCLUSIONS
The development of live poliovaccine marks another
important milestone in the continual advance of preven-
tive medicine. Not only does it promise to protect the
individual against paralytic poliomyelitis but, employed
for the mass vaccination of communities, it also promises
to banish poliomyelitis altogether. This question of mass
vaccination is most important from a public-health point
of view. Langmuir19 has shown that, in communities in
which only part of the susceptible population is adequately
vaccinated, although paralytic poliomyelitis is reduced
among those vaccinated, outbreaks have become more
intense among the unvaccinated. This change for the worse
he attributes to some basic change in the ecology of the
polioviruses and he thinks that this altered epidemiological
pattern may be attributed to the widespread but incom-
plete use of vaccine. It is, therefore, most desirable, if
live poliovaccine is to be employed in the Union of South
Africa, that an attempt should be made to immunize all
persons at risk throughout the country. With the live
vaccine this should be a more feasible proposition than
it is with inactivated vaccine.
In certain favoured countries, the bulk of the population
at risk has been immunized with inactivated vaccine with
very good results. In Denmark20 it was reported that 99%
of the population between 9 months and 14 years had been
immunized, 93% between 15 and 19 years, and 85%
between 20 and 39 years. As a result, only 10 cases of
poliomyelitis were reported in that country last year. It
will, therefore, be readily understandable if such countries
adopt a conservative attitude towards the use of live polio-
vaccine. In the countries where virtually everybody at risk:
has been successfully immunized by inactivated vaccine,
there would seem to be little point in suddenly changing
horses in midstream and also, perhaps, in wasting large
unissued stocks of vaccine.
In South Africa the position is rather different since
there is still a large proportion of unimmunized susceptible
children - children who may not be readily reached by
repeated inoculations with inactivated vaccine but who
may be more readily reached by the simpler process of
feeding with live vaccine. Most important, however, is the
promise that with a mass campaign to cover the whole
country, poliomyelitis may finally be banished as smallpox
has been banished. In conclusion, it must be stressed that,
once we have embarked on this course, there can be no
turning back. If polioviruses are banished from the
environment, no child will be able in future to acquire
a natural immunity by normal and accidental infection.
Feeding of all newborn children with live vaccine at the
earliest age then becomes essential for, should they grow
up without an immunity and the polioviruses return,
disaster will inevitably follow.
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